ArticleClinical and experimental vaccine research2019
A meningococcal B vaccine induces cross-protection against gonorrhea.
Article in Clinical and experimental vaccine research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Article
- Preclinical Evaluation of a Microneedle-Delivered Adjuvanted Microparticulate Gonorrhea Vaccine in Non-Human Primates.Vaccines · 2026Article
- Review
- A Combination Native Outer Membrane Vesicle (NOVM) Vaccine to Prevent Meningococcal and Gonococcal Disease.Pathogens (Basel, Switzerland) · 2025Article
- The Central Importance of Vaccines to Mitigate the Threat of Antibiotic-Resistant Bacterial Pathogens.Vaccines · 2025Review
- Review
- Review
- Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance.International journal of molecular sciences · 2024Review
- Addressing Sexually Transmitted Infections Due toMicroorganisms · 2024Review
- Review
- Outer Membrane Vesicle Vaccine Platforms.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Changing patterns of invasive meningococcal disease and future immunization strategies.Human vaccines & immunotherapeutics · 2023Article
- Evaluating vaccine-elicited antibody activities againstInfection and immunity · 2023Article
- Th1-polarized MtrE-based gonococcal vaccines display prophylactic and therapeutic efficacy.Emerging microbes & infections · 2023Article
- Emerging threat of antimicrobial resistance in Neisseria gonorrhoeae: pathogenesis, treatment challenges, and potential for vaccine development.Archives of microbiology · 2023Review
- Meningococcal disease in North America: Updates from the Global Meningococcal Initiative.The Journal of infection · 2022Review
- Infection With the US Neisseria meningitidis Urethritis Clade Does Not Lower Future Risk of Urethral Gonorrhea.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Meningococcal Detoxified Outer Membrane Vesicle Vaccines Enhance Gonococcal Clearance in a Murine Infection Model.The Journal of infectious diseases · 2022Article
- Outer membrane vesicle vaccines for Neisseria gonorrhoeae.Nature reviews. Urology · 2022Article
- Vaccine Candidates for the Control and Prevention of the Sexually Transmitted Disease Gonorrhea.Vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMATERIALS AND
methodsHealth statistics between 1970 and 2017 were reviewed and the incidence of meningococcal disease and sexually transmitted diseases (gonorrhea, syphilis,
resultsVA-MENGOC-BC was successfully used to control a meningococcal epidemic in Cuba. The strategy to combat the epidemic was carried out in two stages. The first one was a nationwide mass-vaccination campaign from 1989 to 1990, targeting the population at highest-risk aged 3 months to 24 years. During the second stage, begun in 1991, it was included in the Expanded Immunization Program. Gonorrhea incidence increased from 1970 to 1989. However, after the VA-MENGOC-BC massive vaccination campaign a sharp decrease of gonorrhea incidence was observed. It lasted between 1989 and 1993. A second incidence peak was detected in 1995, but it dropped again. Data clearly show a decline in the incidence of gonorrhea following massive vaccination, in contrast with other sexually transmitted diseases. Incidence rates in unvaccinated age groups also decreased, probably due to herd immunity.
conclusionThere is evidence that VA-MENGOC-BC could induce a moderate protection against gonorrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.